NASDAQ:GHRS

GH Research - GHRS Stock Forecast, Price & News

$9.18

+0.09 (+0.99%)

(As of 02/2/2023 12:00 AM ET)

Add

Compare

Today's Range: $8.80
▼
$9.50
50-Day Range: $8.77
▼
$12.30
52-Week Range: $8.46
▼
$20.34

Volume: 36,306 shs
Average Volume: 80,655 shs
Market Capitalization: $463.78 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $46.25

Institutional Ownership

GH Research MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 403.8% Upside
$46.25 Price Target
Short Interest: Bearish
8.92% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.44) to ($1.08) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

810th out of 1,030 stocks

Pharmaceutical Preparations Industry

403rd out of 502 stocks

3.5

Analyst's Opinion

Consensus Rating
GH Research has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $46.25, GH Research has a forecasted upside of 403.8% from its current price of $9.18.
Amount of Analyst Coverage
GH Research has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
8.92% of the float of GH Research has been sold short.
Short Interest Ratio / Days to Cover
GH Research has a short interest ratio ("days to cover") of 56.2, which indicates bearish sentiment.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
GH Research does not currently pay a dividend.
Dividend Growth
GH Research does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GHRS.

2.6

News and Social Media Coverage

News Sentiment
GH Research has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
Search Interest
1 people have searched for GHRS on MarketBeat in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GH Research insiders have not sold or bought any company stock.
Percentage Held by Insiders
41.60% of the stock of GH Research is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
62.55% of the stock of GH Research is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for GH Research are expected to decrease in the coming year, from ($0.44) to ($1.08) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of GH Research is -45.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of GH Research is -45.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
GH Research has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About GH Research (NASDAQ:GHRS) Stock

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

Receive GHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter.

GHRS Stock News Headlines

January 11, 2023 | markets.businessinsider.com

2 Psychedelics Companies Tout Advanced Clinical Trials, Progress With Key Products

November 10, 2022 | finanznachrichten.de

GH Research PLC: GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates

February 2, 2023 | PressReach (Ad)

Top Innovation Stock

Today's stock market report features an AI Robotics tech stock with a $4 million order backlog.

November 10, 2022 | finance.yahoo.com

GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates

October 8, 2022 | health.usnews.com

Massachusetts General Hospital

September 28, 2022 | reuters.com

GHRS.OQ - | Stock Price & Latest News | Reuters

August 23, 2022 | finance.yahoo.com

GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates

May 18, 2022 | finance.yahoo.com

GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates

February 2, 2023 | Investor Place Media (Ad)

Cash Holders STILL Aren't Taking Steps to Prepare

Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.

March 28, 2022 | finance.yahoo.com

GH Research Reports Full Year 2021 Financial Results and Provides Business Updates

March 18, 2022 | msn.com

Field Trip Health, Allied Among Top Psychedelic Movers Of Today

March 11, 2022 | msn.com

Seelos Therapeutics, Mind Medicine Among Top Psychedelic Movers Of Today

February 24, 2022 | msn.com

Psychedelic Stock Gainers And Losers From February 24, 2022

February 7, 2022 | msn.com

Psyched: Psychedelics ETF Launches On NYSE, Psilocybin Trial Approved For Depression, DMT Study Begins

February 2, 2022 | markets.businessinsider.com

New Psychedelics ETF Launches On NYSE Arca

December 6, 2021 | msn.com

Psychedelic Medicine: 5-MeO-DMT Formula For Treatment-Resistant Depression Has Positive Trial Results

November 17, 2021 | msn.com

Mike Tyson: How A Drug Derived From Toad Venom Made Him Comfortable With Dying

September 25, 2021 | benzinga.com

GH Research Q2 2021 G&A Expenses $719K

August 6, 2021 | realmoney.thestreet.com

GH Research Plc (GHRS)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter.

GHRS Company Calendar

Last Earnings: 11/10/2022
Today: 2/02/2023
Next Earnings (Estimated): 3/27/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GHRS
CUSIP: N/A
CIK: 1855129
Web: www.ghres.com
Phone: 353-1437-8443
Fax: N/A
Employees: 14
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $46.25
High Stock Price Forecast: $66.00
Low Stock Price Forecast: $33.00
Forecasted Upside/Downside: +403.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-9,200,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -6.39%
Return on Assets: -6.31%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 76.82
Quick Ratio: 76.82

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.49 per share
Price / Book: 1.67

Miscellaneous

Outstanding Shares: 50,521,000
Free Float: 29,504,000
Market Cap: $463.78 million
Optionable: Not Optionable
Beta: 0.85

Key Executives

Mr. Florian Schonharting M.Sc. (Econ) (Age 53)
Co-Founder & Non-Exec. Chairman

Mr. Theis Terwey M.D. (Age 45)
Co-Founder & CEO

Mr. Magnus Halle (Age 24)
Co-Founder & MD of Ireland

Ms. Julie Ryan A.C.A. (Age 36)
VP of Fin.

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions

GHRS Stock - Frequently Asked Questions

Should I buy or sell GH Research stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GH Research in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GHRS shares.
View GHRS analyst ratings or view top-rated stocks.
What is GH Research's stock price forecast for 2023?: 5 Wall Street research analysts have issued 12 month price targets for GH Research's shares. Their GHRS share price forecasts range from $33.00 to $66.00. On average, they expect the company's stock price to reach $46.25 in the next twelve months. This suggests a possible upside of 408.8% from the stock's current price.
View analysts price targets for GHRS or view top-rated stocks among Wall Street analysts.
How have GHRS shares performed in 2023?: GH Research's stock was trading at $9.72 at the start of the year. Since then, GHRS shares have decreased by 6.5% and is now trading at $9.09.
View the best growth stocks for 2023 here.
When is GH Research's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our GHRS earnings forecast.
How were GH Research's earnings last quarter?: GH Research PLC (NASDAQ:GHRS) posted its quarterly earnings data on Thursday, November, 10th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.16.

When did GH Research IPO?: (GHRS) raised $150 million in an initial public offering (IPO) on Friday, June 25th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share.
What is GH Research's stock symbol?: GH Research trades on the NASDAQ under the ticker symbol "GHRS."
Who are GH Research's major shareholders?: GH Research's stock is owned by many different retail and institutional investors. Top institutional investors include Cornerstone Investment Partners LLC (0.03%), Exchange Traded Concepts LLC (0.02%) and Exchange Traded Concepts LLC (0.02%).
How do I buy shares of GH Research?: Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is GH Research's stock price today?: One share of GHRS stock can currently be purchased for approximately $9.09.
How much money does GH Research make?: GH Research (NASDAQ:GHRS) has a market capitalization of $459.23 million. The company earns $-9,200,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis.
How can I contact GH Research?: The official website for the company is www.ghres.com. The company can be reached via phone at 353-1437-8443 or via email at investors@ghres.com.

This page (NASDAQ:GHRS) was last updated on 2/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

GH Research - GHRS Stock Forecast, Price & News

GH Research MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

Search Interest

Company Ownership

Earnings and Valuation

About GH Research (NASDAQ:GHRS) Stock

GHRS Stock News Headlines

GHRS Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

GHRS Stock - Frequently Asked Questions

Overall MarketRank^™